Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder characterized by left
ventricular hypertrophy, hyperdynamic contraction, and impaired relaxation of the heart …

Variants in> 12 genes encoding sarcomeric proteins can cause various cardiomyopathies.
The two most common are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy …

Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in
hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow …

Background Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often
experience a high burden of symptoms; however, there are no proven pharmacological …

Background: Mavacamten, an orally administered, small-molecule modulator of cardiac
myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic …

Pumping of the heart is powered by filaments of the motor protein myosin that pull on actin
filaments to generate cardiac contraction. In addition to myosin, the filaments contain cardiac …

Myosin modulators are a novel class of pharmaceutical agents that are being developed to
treat patients with a range of cardiomyopathies. The therapeutic goal of these drugs is to …

Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by
MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of …

Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused
by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility …

Contraction in striated muscle is initiated by calcium binding to troponin complexes, but it is
now understood that dynamic transition of myosin between resting, ordered OFF states on …